3 stories mentioning SHA:600062Updated 35d ago
Every FINWIRES story that references SHA:600062, newest first.
China Resources Double-Crane Pharmaceutical (SHA:600062) unit CR Saike obtained drug registration from China's drug regulator for ezetimibe tablets.The drug is used to treat primary hypercholesterolemia, homozygous familial hypercholesterolaemia, and sitosterolemia, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.
China Resources Double-Crane Pharmaceutical (SHA:600062) posted net profit of 501.4 million yuan for the first quarter of 2026, down from 522.7 million yuan a year earlier, according to an April 24 Hong Kong bourse filing by parent China Resources Pharmaceutical (HKG:3320).Revenue fell to 2.81 billion yuan from 3.08 billion yuan in the prior year period.
China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.
